Bank of New York Mellon Corp grew its holdings in shares of Omeros Corporation (NASDAQ:OMER) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 229,959 shares of the biopharmaceutical company’s stock after purchasing an additional 4,376 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.52% of Omeros Corporation worth $4,577,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. State of Wisconsin Investment Board purchased a new stake in shares of Omeros Corporation during the 2nd quarter valued at about $458,000. Rhumbline Advisers increased its position in shares of Omeros Corporation by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock valued at $928,000 after purchasing an additional 832 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Omeros Corporation by 1.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 197,665 shares of the biopharmaceutical company’s stock valued at $3,935,000 after purchasing an additional 2,548 shares during the last quarter. Ingalls & Snyder LLC increased its position in shares of Omeros Corporation by 1.0% during the 2nd quarter. Ingalls & Snyder LLC now owns 5,143,289 shares of the biopharmaceutical company’s stock valued at $102,377,000 after purchasing an additional 50,970 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Omeros Corporation by 87.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 36,160 shares of the biopharmaceutical company’s stock valued at $720,000 after purchasing an additional 16,862 shares during the last quarter. 44.93% of the stock is owned by hedge funds and other institutional investors.

Omeros Corporation (NASDAQ:OMER) opened at 22.86 on Friday. Omeros Corporation has a 52 week low of $7.20 and a 52 week high of $27.09. The company’s market capitalization is $1.02 billion. The company’s 50 day moving average price is $21.02 and its 200-day moving average price is $18.95.

Omeros Corporation (NASDAQ:OMER) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.12. The company had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $14.63 million. The firm’s revenue was up 71.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.32) earnings per share. Equities research analysts expect that Omeros Corporation will post ($1.30) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Bank of New York Mellon Corp Grows Stake in Omeros Corporation (OMER)” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-grows-stake-in-omeros-corporation-omer/1611677.html.

OMER has been the subject of several research reports. BidaskClub raised shares of Omeros Corporation from a “hold” rating to a “buy” rating in a research report on Sunday, June 18th. Maxim Group set a $23.00 price target on shares of Omeros Corporation and gave the company a “buy” rating in a research report on Tuesday, June 13th. Zacks Investment Research raised shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Cantor Fitzgerald set a $15.00 price target on shares of Omeros Corporation and gave the company a “hold” rating in a research report on Tuesday, June 13th. Finally, Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Omeros Corporation in a research report on Wednesday, June 14th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $33.38.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.